Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1

Proteomics

Volumn 11, Issue 21, 2011, Pages 4139-4154

  Thirant, Cécile ^a,b   Varlet, Pascale ^a,b,c   Lipecka, Joanna ^a,b   Le Gall, Morgane ^d   Broussard, Cédric ^d   Chafey, Philippe ^d   Studler, Jeanne Marie ^a,b   Lacombe, Joelle ^a,b,c   Lions, Séverin ^a,b   Guillaudeau, Angélique ^e   Camoin, Luc ^d   Daumas Duport, Catherine ^a,b,c   Junier, Marie Pierre ^a,b,c   Chneiweiss, Hervé ^a,b  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d INSTITUT COCHIN   (France)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

2 D DIGE; Cell biology; Gliomas; Human; IDH1

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PROTEOME; ISOCITRATE DEHYDROGENASE;

ADULT; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; GENE DELETION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION; UNINDEXED SEQUENCE; WILD TYPE; AGED; BRAIN TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84856596373     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000646     Document Type: Article

References (47)

1. Louis, D. N., Oghaki, K., Wiestler, O. D., Cavenee, W. K., WHO Classification of Tumors of the Central Nervous System. IARC Press, Lyon, France 2007.
2. Daumas-Duport, C., Varlet, P., Tucker, M. L., Beuvon, F. et al., Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J. Neurooncol. 1997, 34, 37-59.
3. McCarthy, B. J., Propp, J. M., Davis, F. G., Burger, P. C., Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 2008, 30, 34-44.
4. Daumas-Duport, C., Koziak, M., Miquel, C., Nataf, F. et al., Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies. Neurochirurgie 2005, 51, 247-253.
5. Daumas-Duport, C., Tucker, M. L., Kolles, H., Cervera, P. et al., Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J. Neurooncol. 1997, 34, 61-78.
6. Kros, J. M., Grading of gliomas: the road from eminence to evidence. J. Neuropathol. Exp. Neurol. 2011, 70, 101-109.
7. Quon, H., Hasbini, A., Cougnard, J., Djafari, L. et al., Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. J. Neurooncol. 2010, 96, 277-285.
8. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C. et al., An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
9. Yan, H., Parsons, D. W., Jin, G., McLendon, R. et al., IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360, 765-773.
10. Sanson, M., Marie, Y., Paris, S., Idbaih, A. et al., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009, 27, 4150-4154.
11. Ichimura, K., Pearson, D. M., Kocialkowski, S., Backlund, L. M. et al., IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol. 2009, 11, 341-347.
12. Capper, D., Reuss, D., Schittenhelm, J., Hartmann, C. et al., Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2010, 121, 241-252.
13. Dang, L., White, D. W., Gross, S., Bennett, B. D. et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739-744.
14. Zhao, S., Lin, Y., Xu, W., Jiang, W. et al., Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324, 261-265.
15. Frezza, C., Tennant, D. A., Gottlieb, E., IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 2010, 17, 7-9.
16. van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A. et al., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 2010, 16, 1597-1604.
17. Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K. et al., IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2011, 75, 1560-1566.
18. Varlet, P., Soni, D., Miquel, C., Roux, F. X. et al., New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 2004, 55, 1377-1391: discussion 1391-1372.
19. Riederer, B. M., Non-covalent and covalent protein labeling in two-dimensional gel electrophoresis. J. Proteomics 2008, 71, 231-244.
20. Ahmed, F. E., Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches. Exp. Rev. Proteomics 2008, 5, 841-864.
21. Shevchenko, A., Loboda, A., Ens, W., Schraven, B., Standing, K. G., Archived polyacrylamide gels as a resource for proteome characterization by mass spectrometry. Electrophoresis 2001, 22, 1194-1203.
22. Duplan, L., Bernard, N., Casseron, W., Dudley, K. et al., Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death. J. Neurosci. 2010, 30, 785-796.
23. Stemmer-Rachamimov, A. O., Louis, D. N., Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr. Opin. Oncol. 1997, 9, 230-234.
24. Ducray, F., Idbaih, A., de Reynies, A., Bieche, I. et al., Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol. Cancer 2008, 7, 41.
25. Ducray, F., Criniere, E., Idbaih, A., Mokhtari, K. et al., alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology 2009, 72, 156-161.
26. Barbashina, V., Salazar, P., Holland, E. C., Rosenblum, M. K., Ladanyi, M., Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 2005, 11, 1119-1128.
27. Pandita, A., Balasubramaniam, A., Perrin, R., Shannon, P., Guha, A., Malignant and benign ganglioglioma: a pathological and molecular study. Neuro. Oncol. 2007, 9, 124-134.
28. Horbinski, C., Dacic, S., McLendon, R. E., Cieply, K. et al., Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathol. 2009, 19, 439-448.
29. Rousseau, E., Palm, T., Scaravilli, F., Ruchoux, M. M. et al., Trisomy 19 ependymoma, a newly recognized geneticohistological association, including clear cell ependymoma. Mol. Cancer 2007, 6, 47.
30. Nakopoulou, L., Kerezoudi, E., Thomaides, T., Litsios, B., An immunocytochemical comparison of glial fibrillary acidic protein, S-100p and vimentin in human glial tumors. J. Neurooncol. 1990, 8, 33-40.
31. Geiger, K. D., Stoldt, P., Schlote, W., Derouiche, A., Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am. J. Pathol. 2000, 157, 1785-1793.
32. Wonsey, D. R., Zeller, K. I., Dang, C. V., The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc. Natl. Acad. Sci. USA 2002, 99, 6649-6654.
33. Mao, Y. W., Liu, J. P., Xiang, H., Li, D. W., Human alphaA-and alphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ. 2004, 11, 512-526.
34. Shoshan, Y., Nishiyama, A., Chang, A., Mork, S. et al., Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl. Acad. Sci. USA 1999, 96, 10361-10366.
35. Ligon, K. L., Alberta, J. A., Kho, A. T., Weiss, J. et al., The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 2004, 63, 499-509.
36. Smith, J. S., Wang, X. Y., Qian, J., Hosek, S. M. et al., Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol. 2000, 59, 495-503.
37. Soichi, O., Masanori, N., Hideo, T., Kazunori, A. et al., Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. Neurosurgery 2007, 60, 707-714; discussion 714.
38. Okamoto, H., Li, J., Glasker, S., Vortmeyer, A. O. et al., Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol. Ther. 2007, 6, 391-396.
39. Rostomily, R. C., Born, D. E., Beyer, R. P., Jin, J. et al., Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J. Proteome Res. 2010, 5, 2610-2618.
40. Iizuka, N., Hirose, K., Noma, T., Hazama, S. et al., The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br. J. Cancer 1999, 81, 469-475.
41. Ferguson, A. W., Flatow, U., MacDonald, N. J., Larminat, F. et al., Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res. 1996, 56, 2931-2935.
42. Jung, S., Paek, Y. W., Moon, K. S., Wee, S. C. et al., Expression of Nm23 in gliomas and its effect on migration and invasion in vitro. Anticancer Res. 2006, 26, 249-258.
43. Wick, W., Grimmel, C., Wild-Bode, C., Platten, M. et al., Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J. Neurosci. 2001, 21, 3360-3368.
44. Vander Heiden, M. G., Cantley, L. C., Thompson, C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324, 1029-1033.
45. Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T. W. et al., Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2, ra73.
46. Tong, X., Zhao, F., Thompson, C. B., The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 2009, 19, 32-37.
47. Kase, S., He, S., Sonoda, S., Kitamura, M. et al., alphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 2010, 115, 3398-3406.